Corporate$TTRX4:01 PM ET

Turn Therapeutics CEO and Clinical Lead to join BTIG fireside chat on atopic dermatitis strategy

By BORSA NewsroomPublished Oct 21, 2026, 4:01 PM EDTUpdated Oct 21, 2026, 4:02 PM EDT

Turn Therapeutics (TTRX) announced its CEO and clinical lead will participate in a U.S. Bancorp | BTIG virtual fireside chat on October 28 at 10:00 AM ET. The discussion will cover the company's strategy for developing GX-03 in atopic dermatitis. The event is for institutional clients.

Sentimentneutral 50

Neutral · 50 of 100

Impact10

low · stays off the top drivers

Confidence90%

high confidence · single wire

Eventdeveloping

v1 · alerted to followers

WHAT WE KNOW

Turn Therapeutics (TTRX) is a clinical-stage biotech focused on non-systemic therapies for inflammatory skin diseases.